135 results about "Bifidobacterium bifidum" patented technology

The invention belongs to the technical field of microorganisms, and particularly relates to bifidobacterium longum subsp. Longum as well as a composition, a pharmaceutical composition, a culture, a food product or a dietary supplement containing the bifidobacterium longum subsp. Longum and application of the bifidobacterium longum subsp. Longum. The bifidobacterium longum is preserved in the Guangdong Microbial Culture Collection Center on January 21, 2025, and the preservation number is GDMCC (China General Microbiological Culture Collection Center) No.65836. The bifidobacterium longum subsp. Longum has relatively strong gastric acid and cholate tolerance and intestinal colonization capability; the bifidobacterium longum subsp. Longum can effectively utilize bifidobacterium bifidum to release monosaccharide or disaccharide outside cells for efficient proliferation, and the composition containing the bifidobacterium longum subsp. Longum, the bifidobacterium bifidum and breast milk oligosaccharide can release a large amount of short-chain fatty acid, so that the effects of maintaining the physiological function of an organism and improving the health of the organism are achieved.

The invention relates to the technical field of microorganisms, in particular to bifidobacterium bifidum BGLP1 capable of regulating sugar digestion and producing GLP-1 at high yield and application of the bifidobacterium bifidum BGLP1. The preservation number of the bifidobacterium bifidum BGLP1 is CGMCC (China General Microbiological Culture Collection Center) No.35718, and the bifidobacterium bifidum BGLP1 can be used for preparing the feed additive. The strain has the capability of inhibiting alpha-glucosidase and alpha-amylase; sTC-1 cells are stimulated to secrete GLP-1, and the blood glucose reducing pathway capacity of the intestinal tract is activated; the activity of pancreatic lipase is obviously inhibited, and the dietary fat absorption capability can be effectively reduced; redundant cane sugar is converted into exopolysaccharide, so that the probiotic function capability is improved; the capability of converting white fat into brown fat is promoted; macrophages are activated, and the body immune function is improved. In addition, the bifidobacterium bifidum BGLP1 also has relatively strong intestinal colonization ability, has good tolerance in artificial gastric juice and artificial intestinal juice, and can smoothly reach the intestinal tract of a human body.

The invention provides a cobalt monatomic nano-enzyme system modified by phospholipid polyethylene glycol carboxyl. The cobalt monatomic nano-enzyme system comprises a cobalt monatomic nano-enzyme composite core and phospholipid polyethylene glycol carboxyl compounded on the surface of cobalt monatomic nano-enzyme, the cobalt monatomic nano-enzyme composite core comprises a cobalt monatomic nano-enzyme and ginsenoside loaded on the cobalt monatomic nano-enzyme. The invention also provides a bifidobacterium synergetic cobalt monatomic nano-enzyme system which is formed by combining cobalt monatomic nano-enzyme with ginsenoside Rb1 and further delivering the cobalt monatomic nano-enzyme and ginsenoside Rb1 through bifidobacterium bifidum for targeted therapy of enteritis. The combination of Co SA and Rb1 can enhance the anti-inflammatory efficacy by adjusting a key immune signal pathway, and bifidobacterium bifidum can ensure targeted delivery of microbiota and promote intestinal barrier repair. The synergistic three-component strategy integrating monatomic nano-enzyme antioxidation, natural drug immunoregulation and probiotic targeting is provided, and a promising treatment platform is provided for accurate intervention of IBD.

The invention relates to the technical field of probiotics, in particular to a lactic acid bacteria strain composition with an effect of improving sleep quality and application. The lactic acid bacteria strain composition comprises a bifidobacterium breve BBr-28 strain, a bifidobacterium animalis subsp. Lactis PS23 strain, a bifidobacterium longum subsp. Infantis BR631 strain, a bifidobacterium bifidum BD-188 strain and a plant lactobacillus PQQ-1 strain. The lactic acid bacteria strain composition has the physiological activity function of improving the sleep quality, so that the lactic acid bacteria strain composition can be used for preparing food or composition for improving the sleep quality, and the problem of poor sleep quality is solved.

The invention belongs to the technical field of food processing, and particularly relates to fermented beef jerky and a preparation method thereof. The preparation method of the beef jerky comprises the following steps: (1) removing fascia and fat from fresh cattle hind leg meat, washing with clear water, and cutting into meat slices; (2) adding table salt, glucose, white granulated sugar and sodium nitrite into the sliced meat, uniformly mixing, adding a fermentation inoculant which comprises staphylococcus calcaratus, pediococcus acidilactici, bifidobacterium bifidum and Witzia ciliaris, and fermenting; and (3) after fermentation, drying and cooling to obtain the fermented beef jerky. Specific strains are selected to form a fermentation inoculant for fermentation, and the prepared fermented beef jerky is high in free amino acid and soluble peptide content, low in nitrite residual quantity, uniform red brown in color and slightly bright in surface, and belongs to high-quality beef jerky.

The invention provides a cordyceps militaris fermentation extract and application thereof in preservation of agaricus bisporus, and belongs to the technical field of deep processing of edible mushrooms and preservation of agricultural products. The preparation method of the cordyceps militaris fermentation extract comprises the following steps: (1) taking cordyceps militaris sporocarp, adding water, grinding, and performing enzymolysis by using cellulase and papain in sequence to obtain cordyceps militaris pulp; (2) adding glucose and waste beer yeast powder into the cordyceps militaris pulp, then inoculating lactobacillus paracasei and bifidobacterium bifidum, and fermenting; and (3) after fermentation is completed, carrying out ultrasonic crushing, centrifuging to remove thalli, and carrying out spray drying to obtain the cordyceps militaris fermentation extract. The method can effectively reduce the browning index and weight loss ratio of agaricus bisporus, can slow down the increase of malonaldehyde, reduces the activity of PPO enzyme, and prevents enzymatic browning caused by the synergistic effect of the PPO enzyme and peroxidase. The SOD enzyme activity in the agaricus bisporus can be kept, active oxygen in tissues can be removed, and the metabolic balance of the active oxygen can be maintained.

The invention provides application of a probiotic composition in preparation of a medicine for preventing and / or treating Alzheimer's disease, and belongs to the technical field of probiotic medical application. The probiotic composition disclosed by the invention is prepared from lactobacillus rhamnosus, bifidobacterium lactis and bifidobacterium bifidum. According to the probiotic composition disclosed by the invention, on the phylum level, the relative abundance of Verrucomicrobiota (verruca microflora phylum) is improved by the probiotic composition, and the relative abundance of the verrucomicrobiota (verruca microflora phylum) is improved by the probiotic composition; in the level of genus, the probiotic composition increases the relative abundance of the beneficial bacteria genus Akkermansia (Ackermania genus) and Bifidobacterium (Bifidobacterium genus), and in the level of genus Akkermania (Ackermania genus) and Bifidobacterium (Bifidobacterium genus); the behavioral cognition level can be remarkably improved, neuron injury is improved, and intestinal barrier injury is improved.

Disclosed in the present invention is a probiotic. The probiotic comprises Parabacteroides distasonis with the microbial deposit number of CCTCC NO: M20222033, Limosilactobacillus fermentum with the microbial deposit number of CCTCC NO: M2023352, Lactobacillus salivarius with the microbial deposit number of CCTCC NO: M2023348, Enterococcus avium with the microbial deposit number of CCTCC NO: M2023350, and Bifidobacterium bifidum with the microbial deposit number of CCTCC NO: M2023349. The probiotic has good safety, has antioxidant activity, can inhibit pathogenic bacteria, can alleviate colon injury, can inhibit inflammation, and can alleviate diarrhea caused by chemotherapeutic drugs.

The invention belongs to the field of biological medicine, and particularly relates to bifidobacterium bifidum and application of the bifidobacterium bifidum in eye health products, and the bifidobacterium bifidum BB00 has the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.34389. The invention further discloses a preparation method of the bifidobacterium bifidum. The bifidobacterium bifidum BB00 can improve clinical symptoms of xerophthalmia, increase tear secretion amount, prolong tear film rupture time, reduce ocular surface disease indexes, relieve corneal epithelium injury, adjust the opening degree of palpebral fissure, adjust intestinal flora composition, improve flora diversity and inhibit growth of intestinal pathogenic bacteria. The bifidobacterium bifidum BB00 not only provides an innovative solution for a clinical pain point of xerophthalmia and realizes synergistic intervention of intestinal regulation and eye health, but also has scientific innovation, clinical effectiveness and industrialization potential, and has important value for application of bacteria and fungicide in the field of biological medicine and treatment of ocular surface-intestinal tract related diseases.

The invention discloses a beta-galactosidase mutant derived from bifidobacterium bifidum and application thereof, and belongs to the technical field of enzyme engineering. The invention aims to improve the GOS synthesis yield and shorten the treatment time. The invention provides a beta-galactosidase mutant derived from bifidobacterium, and the mutant is obtained by mutating a 531 site, a 682 site, a 747 site or a 710 site by taking SEQ ID No.1 as a starting sequence. The glucoside conversion rate of the mutant W710F after reacting in a 350g / L lactose system for 5 hours reaches 45.90%, and is increased by 53.87% compared with that of a wild type. The beta-galactosidase mutant has the excellent properties of high catalytic efficiency and high yield of galactooligosaccharide, the cost of prebiotics is reduced, the conversion efficiency of producing galactooligosaccharide by using the beta-galactosidase mutant is improved, and the beta-galactosidase mutant has great industrial production and application potential and economic value.

The invention relates to application of lactobacillus helveticus HH-LPH17 in preparation of medicine for assisting in relieving inflammatory bowel diseases and relates to the technical field of probiotic compositions.The probiotic composition for treating the inflammatory bowel diseases comprises, by weight, 10 parts to 80 parts of lactobacillus johnsonii LBJ 456, 10 parts to 60 parts of lactobacillus helveticus HH-LPH17, 10 parts to 60 parts of lactobacillus acidophilus HH-LA26 and 10 parts to 60 parts of bifidobacterium longum HH-BL18. The composition comprises the following components in parts by weight: 10-60 parts of bifidobacterium bifidum HH-BB27 and 10-60 parts of bifidobacterium longum subspecies infantis HH-BI27. According to the probiotic composition for treating the inflammatory bowel disease, probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for treating the inflammatory bowel disease is prepared, and a novel safe and effective adjuvant therapy method is provided for treatment of the inflammatory bowel disease.

The invention discloses a Bifidobacterium bifidum CCFM1424 capable of relieving senescence and an application of the Bifidobacterium bifidum CCFM1424, and belongs to the technical field of microorganisms. The bifidobacterium bifidum CCFM1424 disclosed by the invention can be used for effectively relieving cognitive defects of aged mice, improving the oxidation resistance (SOD, CAT, MDA and GSH-Px) of the brain and the liver, reducing the levels of proinflammatory factors TNF-alpha, IL-1beta and IL-6 in serum and relieving colitis. In addition, the intervention of the bifidobacterium bifidum CCFM1424 can maintain muscle health, and can improve the change of intestinal flora and intestinal metabolites related to aging. According to the bifidobacterium bifidum, the application range of the bifidobacterium bifidum as probiotics is expanded, and the bifidobacterium bifidum has a huge application prospect in the aspect of relieving senescence.

The invention relates to a probiotic composition for treating rheumatoid arthritis and application thereof, and relates to the technical field of probiotic compositions.The probiotic composition for treating rheumatoid arthritis is prepared from, by weight, 10-40 parts of lactobacillus johnsonii LBJ 456, 10-30 parts of lactobacillus helveticus HH-LPH17 and 10-30 parts of lactobacillus acidophilus HH-LA26. The bifidobacterium longum subsp. Longum HH-BL18, the bifidobacterium bifidum HH-BB27 and the bifidobacterium longum subsp. Infantis HH-BI27 are prepared from the following raw materials in parts by weight: 10 to 40 parts of bifidobacterium longum subsp. Probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for treating rheumatoid arthritis is prepared, and a novel safe and effective adjuvant therapy method is provided for treatment of RA.

The invention relates to the technical field of medicinal and edible beverages, and discloses a formula and a preparation method of a ginseng probiotic fermented beverage. The ginseng probiotic fermented beverage is prepared from ginseng, fructus lycii, rhizoma polygonati, poria cocos, fructus crataegi, honey and a compound probiotic group. The beverage comprises the following raw materials in parts by weight: 5-15 parts of ginseng; 3-8 parts of fructus lycii; 2-5 parts of rhizoma polygonati; 1-3 parts of poria cocos; 3-6 parts of hawthorn; 5-10 parts of honey; the viable count of the composite probiotic group is (1-3) * 10 < 9 > CFU / mL; according to the preparation method, the medicinal and edible raw materials are subjected to enzymolysis and three-stage temperature-controlled fermentation, so that the release rate and the stability of active ingredients such as polysaccharide and saponin are improved; through synergistic interaction of lactobacillus plantarum, lactobacillus acidophilus and bifidobacterium bifidum in a ratio of 2: 1: 1, intestinal flora regulation and immune enhancement functions are enhanced; in addition, three-stage temperature control fermentation is combined with micro-aerobic regulation and control, a flora metabolism path is optimized, micromolecular active substances are enriched, thalli and macromolecular impurities are removed through a centrifugal combined ultrafiltration process, and the purity and the absorption rate of the active ingredients can be improved.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium bifidum NKUFB3-12 and a composition thereof in preparation of products for relieving allergic diseases and / or regulating intestinal flora caused by allergy. The preservation number of the bifidobacterium bifidum NKUFB3-12 is GDMCC (China General Microbiological Culture Collection Center) No. 64013. The bifidobacterium bifidum NKUFB3-12 disclosed by the invention has excellent functional characteristics of relieving allergic diseases and regulating allergic intestinal flora, and also has excellent probiotic characteristics of acid resistance, cholate resistance and oxidation resistance, and the strain is safe and has no adverse side effect after being taken. The invention provides a composition. The composition comprises bifidobacterium bifidum NKUFB3-12 and 2 '-fucosyllactose (2'-FL), and the NKUFB3-12 is compounded with the 2 '-FL to show an effective inhibition effect on the imbalance of allergic immune response.

The invention provides ginseng freeze-dried powder capable of resisting oxidation, improving immunity and inhibiting cancer cell diffusion and a preparation method of the ginseng freeze-dried powder, and belongs to the technical field of ginseng processing. According to the ginseng freeze-dried powder researched and developed by the invention, three traditional Chinese medicinal materials including ginseng, lucid ganoderma and radix ophiopogonis are selected, the performance is improved through synergistic fermentation of bifidobacterium bifidum CICC-6168 and lactobacillus helveticus CICC-6273, then the ginseng freeze-dried powder is prepared by utilizing a vacuum freeze-drying technology, and the prepared product has the effects of resisting oxidation, improving immunity, inhibiting cancer cell diffusion and reducing uric acid.

The invention belongs to the technical field of microorganisms, and particularly discloses bifidobacterium bifidum FL276.1 and application thereof. In particular to bifidobacterium bifidum FL276.1 which is preserved in the China Center for Type Culture Collection on June 25, 2021, the preservation address is Wuhan University, Wuhan, Hubei province, and the preservation number is CCTCC M 2021772. The invention discloses bifidobacterium bifidum FL276.1 and application thereof, and the bifidobacterium bifidum FL276.1 can regulate intestinal flora disorder caused by ETEC infection, can reduce death rate caused by ETEC infection, effectively resists ETEC infection, and can be widely applied to preparation of freeze-dried bacterial powder, dairy products and other probiotic products.

The invention provides a composition of probiotics and LNT (Lipoprotein Nitrate), wherein the probiotics are selected from one or two of Bifidobacterium breve BB-G95 (Bifidobacterium breve BB-G95) and Bifidobacterium bifidum BB-G90 (Bifidobacterium bifidum BB-G90). The probiotic is capable of efficiently utilizing LNT, so that the composition can be used at least in the following aspects: increasing the metabolic activity of the intestinal microbiota of a subject taking the composition; improving transplantation and / or survival of bifidobacteria in the intestinal tract of a subject taking the composition; promoting the growth and / or survival of beneficial bacteria in the intestinal tract of a subject taking the composition; promoting metabolism of short chain fatty acids in the intestinal tract of a subject taking the composition; treating, preventing and / or reducing inflammation or infection in a subject taking the composition.

The application provides a coffee peel enzyme fermentation agent and a preparation method of the enzyme, and belongs to the technical field of enzyme production.The preparation method of the coffee peel enzyme comprises the following steps: mixing coffee peel powder and sugar of sweetener oil residue, and sequentially performing fermentation of Saccharomyces cerevisiae YNXC003 and anaerobic fermentation of Bifidobacterium bifidum YNXC004 to obtain the coffee peel enzyme.The coffee peel powder and the sugar of sweetener oil residue are used as composite raw materials, special bacterial agents are combined, and a segmented fermentation mode is adopted, so that the nutritional activity of the two raw materials can be fully released, the nutritional level and flavor taste of the enzyme can be significantly improved, and the enzyme can be endowed with physiological functions such as blood sugar reduction.The total acid content of the coffee peel enzyme is 8-12 g / L, the total phenol content is 1.5-2.5 g / L, the coffee peel enzyme is rich in bioactive substances such as short-chain fatty acids, polyphenol compounds and amino acids, and has a significant blood sugar reduction effect.

Provided is a Bifidobacterium bifidum strain, Bifidobacterium bifidum ibiome001, which can significantly reduce body weight gain and white adipose tissue weight gain of high fat diet-induced obese and diabetic mice, and enhances expression of lipolytic genes ATGL and HSL. Moreover, Bifidobacterium bifidum ibiome001 can significantly lower fasting blood glucose levels, area under curves (AUCs) of the oral glucose tolerance (OGTT) curve, plasma glycated hemoglobin levels and insulin levels of diabetic mice. It is suggested that Bifidobacterium bifidum ibiome001 is a promising potential probiotic strain for the treatment of metabolic syndrome such as obesity, diabetes and the like, which is more effective than other Bifidobacterium strains / compositions.

The application provides bifidobacterium longum MG-G763 for improving constipation, and belongs to the technical field of microorganisms. The bifidobacterium longum MG-G763 provided by the application can effectively relieve constipation by integrating multiple effects such as nerve regulation, immune regulation, barrier repair and flora regulation, and systematically restoring intestinal function homeostasis. The bifidobacterium longum MG-G763 can significantly improve the defecation particle number and defecation weight of constipated mice, shorten the time for defecating the first black stool, improve the small intestinal transport rate of the mice, effectively improve and relieve the defecation condition of the constipated mice, and significantly increase the amount of intestinal beneficial bacteria and reduce the amount of harmful bacteria, thereby promoting intestinal health.

In some embodiments, a composition comprising Bifidobacterium bifidum, Bifidobacterium longum, Lactobacillus plantarum, and Streptococcus thermophilus is provided. In some embodiments, provided is the use of a composition of any of the examples herein for preventing or alleviating anxiety and / or sensory hypersensitivity, preventing or treating autism spectrum disorder (ASD), anxiety disorder and / or gastrointestinal (GI) disorder or condition, enhancing attention and / or concentration, or stimulating a GABA receptor in a subject. In some embodiments, methods and kits are provided for preventing or alleviating anxiety and / or sensory hypersensitivity, preventing or treating autism spectrum disorders, anxiety disorders, and / or gastrointestinal disorders or conditions, enhancing attention and / or concentration, or stimulating GABA receptors in a subject. In certain embodiments, the compositions are safe to use and effective to prevent or alleviate anxiety and / or sensory hypersensitivity in subjects, particularly children subjects.

Use of a composition comprising bacteria for odor reduction in the treatment of symptoms of tissue necrosis, wound secretions or putrid wounds or a disease selected from the group consisting of ozena, hyperhidrosis, osmidrosis, chronic urinary tract infections, chlamydial infections and halitosis; wherein the composition comprises the bacteria Lactobacillus acidophilus TYCA15, Lactobacillus salivarius, Bifidobacterium animalis, Bifidobacterium bifidum and Bifidobacterium longum in the ratio 1:1:1:1:1; and the composition totals 10 9 bacteria per gram of the composition.

The present invention provides a Bifidobacterium bifidum postbiotic with enhanced intestinal barrier function, its preparation method and application. The preparation method of the postbiotic includes: centrifuging to obtain viable Bifidobacterium bifidum FL-228.1 from the fermentation broth of Bifidobacterium bifidum FL-228.1, and performing optimal heat treatment on the viable bacteria to obtain inactivated Bifidobacterium bifidum FL-228.1 postbiotic; the conditions of the optimal heat treatment are: the temperature is 60-80 °C, and the time is 15-25 min. The present invention inactivates Bifidobacterium bifidum FL-228.1 by using a specific combination of temperature and time, and the obtained Bifidobacterium bifidum postbiotic has the best effect of enhancing intestinal barrier function, and can be used for preparing drugs or health foods for preventing intestinal barrier damage and enhancing intestinal barrier function.

The invention provides a sugarcane fermentation product, a food quality guarantee product, a preparation method and application, and particularly belongs to the technical field of food preservation. The preparation method of the sugarcane leavening comprises the following steps: crushing sugarcane, and performing first sterilization to obtain sterile sugarcane pulp; inoculating the compound bacteria into the sterile sugarcane pulp for fermentation; the compound bacteria comprise lactic acid bacteria, bifidobacterium bifidum and propionibacterium; a degerming compound enzyme is supplemented in the fermentation process; the compound enzyme comprises xylanase, sucrase, phytase and aminopeptidase; and after fermentation, carrying out secondary sterilization, filtering, and discarding filter residues to obtain the sugarcane fermentation product. The sugarcane leavening disclosed by the invention is prepared from natural raw materials, has good anti-corrosion and anti-oxidation effects, and can prolong the shelf life of food.

The invention relates to a nutritional composition for improving an intestinal immune function and application thereof, and belongs to the technical field of microorganisms. The nutritional composition of the present invention comprises a bifidobacterium bifidum (Bifidobacterium bifidum), and a breast milk oligosaccharide. The breast milk oligosaccharide in the nutritional composition can provide a growth substrate for the bifidobacteria and promote colonization of the bifidobacteria in intestinal tracts. The bifidobacterium bifidum produces beneficial metabolites by metabolizing oligosaccharide in breast milk, and plays an immune regulation role. According to the nutritional composition, the intestinal immune function is remarkably improved, the intestinal flora structure is optimized, and the risk of immune-related diseases is reduced.

Provided is a mixed strain with both excellent anti-inflammatory activity and excellent productivity, including Bifidobacterium animalis subsp. lactis LM1017 (Accession No. KCCM12629P), Bifidobacterium n breve LM1092 (Accession No. KCCM13464P), Bifidobacterium longum LM1024 (Accession No. KCCM12919P), and Bifidobacterium bifidum LM1108 (Accession No. KCCM13463P). The strain provided herein has an excellent commercial viability of probiotics.

The present invention relates to bacteria, compositions and methods for their production, and prebiotic compositions. By the present invention, novel Bifidobacterium bacteria having assimilation ability of two or more HMOs are provided. The bacteria are selected from the group consisting of Bifidobacterium longum subsp. infantis (NITE BP-03068), Bifidobacterium bifidum (NITE BP-03058), and Bifidobacterium bifidum (NITE BP-03067).

The present application relates to the technical field of microorganisms, and particularly relates to a bifidobacterium BGLP1 capable of regulating sugar digestion and high GLP-1 production and application thereof. Bifidobacterium bifidum The bifidobacterium BGLP1 (CGMCC No. 35718) has the abilities of inhibiting alpha-glucosidase and alpha-amylase, stimulating STC-1 cells to secrete GLP-1 and activating the intestinal glucose-lowering pathway, significantly inhibiting pancreatic lipase activity and effectively reducing dietary fat absorption, converting excess sucrose into extracellular polysaccharides to increase the probiotic function, promoting the conversion of white fat into brown fat, and activating macrophages and improving the immune function of the body. In addition, the bifidobacterium BGLP1 has strong intestinal colonization ability, has good tolerance in artificial gastric juice and artificial intestinal juice, and can successfully reach the human intestinal tract.

The invention discloses targeted probiotic dietary powder for conditioning intestinal microecology and a preparation method of the targeted probiotic dietary powder. According to the invention, the micro-ecological health of intestinal tracts is obviously improved through a triple synergistic mechanism. The core probiotic combination directly acts on the key link of intestinal flora imbalance. Lactobacillus plantarum LP-12 inhibits excessive release of intestinal inflammatory factors and alleviates intestinal mucosa damage. The bifidobacterium bifidum TMC3115 enhances tight connection of intestinal epithelial cells and repairs a physical barrier; the Witzia ciliaris MKSWC01 can degrade endotoxin and block the chain reaction of chronic inflammation. Meanwhile, the fucoidin and the galactooligosaccharide are used for accurately feeding the probiotics and enhancing the colonization capability of the probiotics in a colon mucus layer, so that long-acting protection is formed. L-glutamine provides basic nutrition required by intestinal mucosa regeneration, and resistant dextrin continuously generates short-chain fatty acid to maintain a weak acid environment of colon, so that healthy flora ecology is comprehensively reconstructed.